Chinese patent medicine

ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents

Retrieved on: 
Wednesday, November 8, 2023
Medical Devices, Health, Hospitals, Surgery, Health Technology, Biotechnology, Chinese patent medicine, Intellectual property, Chinese, 1836 U.S. Patent Office fire, NDRA, Process, Isolation, IP, Microscope

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S. and two in China.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S. and two in China.
  • ENDRA’s intellectual property (IP) portfolio now includes 70 issued patents worldwide, enhancing the IP protection for the novel TAEUS® system.
  • 11806113, titled “Thermoacoustic Probe,” relates to a novel thermoacoustic probe with an optical transducer and an integrated wedge.
  • “These newly issued patents protect and further differentiate ENDRA's thermoacoustic systems in areas of high unmet clinical need, such as the early detection of steatotic liver disease."

TANAKA Succeeds in Developing World's First High-Entropy Alloy Powder Composed Only of Precious Metals

Retrieved on: 
Wednesday, October 25, 2023
3D, Palladium, Patent, Rhodium, Nano, RH, Engineering, Particle size, Powder, Alloy, Physics, Ruthenium, Head, Platinum, Chinese patent medicine, Iridium, Sintering

(Head office: Chiyoda-ku, Tokyo; CEO: Koichiro Tanaka), which develops industrial precious metals products as one of the core companies of TANAKA Precious Metals, announced that it has succeeded in creating a high-entropy alloy powder composed of precious metals with a fine particle size of 10um or less high crystallinity and excellent composition uniformity.

Key Points: 
  • (Head office: Chiyoda-ku, Tokyo; CEO: Koichiro Tanaka), which develops industrial precious metals products as one of the core companies of TANAKA Precious Metals, announced that it has succeeded in creating a high-entropy alloy powder composed of precious metals with a fine particle size of 10um or less high crystallinity and excellent composition uniformity.
  • This product is the world's first high-entropy alloy powder composed of only five precious metals: platinum (Pt), palladium (Pd), iridium (Ir), ruthenium (Ru), and rhodium (Rh).
  • TANAKA has already established a mass production process for this product and plans to begin providing samples in October.
  • The precious metal alloy powders in this product are alloys composed only of five or more precious metal elements that maintain the corrosion resistance, electrical conductivity, and other excellent properties of precious metals.

LUMINELLE Announces China National Intellectual Property Administration’s Decision to Grant Issuance of Patent for LUMINELLE Bx (Biopsy) System, Expanding Global Footprint

Retrieved on: 
Thursday, October 5, 2023
Oncology, Medical Devices, Health, Consumer, Women, Biotechnology, Patent, Cancer, Food, China National Intellectual Property Administration, American Society of Clinical Oncology, CNIPA, Death, Mortality, Disease, Uterine cancer, Anesthesia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Chinese patent medicine, Woman, Medical imaging, Biopsy

LUMINELLE (UVision360, Inc.), an innovative medical device company, announces today that the China National Intellectual Property Administration (CNIPA) has issued Chinese Patent No.

Key Points: 
  • LUMINELLE (UVision360, Inc.), an innovative medical device company, announces today that the China National Intellectual Property Administration (CNIPA) has issued Chinese Patent No.
  • 201880086268.8 titled “Biopsy Device and Method” for the LUMINELLE Bx System.
  • Issued on September 22, 2023, the new patent provides LUMINELLE with international intellectual property rights and allows the company to expand its technological footprint beyond the U.S. borders.
  • “The patent issuance from the CNIPA is a significant milestone for LUMINELLE as we continue to develop life-changing diagnostics for women everywhere,” said LUMINELLE CEO Allison London Brown.

South Rampart Pharma Further Expands Patent Portfolio for SRP-001 with Composition of Matter Patent in China

Retrieved on: 
Thursday, July 6, 2023
China National Intellectual Property Administration, Patent, CNIPA, Chinese patent medicine, United States Patent and Trademark Office, European Patent Office, IP, EPO, Pain, Paracetamol, European Patent Convention, Liver, Chronic pain, Pharmaceutical industry

NEW ORLEANS, July 6, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that the China National Intellectual Property Administration (CNIPA) has granted the Company a new patent covering the composition of matter of SRP-001, South Rampart's novel, non-opioid new chemical entity that avoids the liver toxicity associated with acetaminophen. The Company is currently developing SRP-001 for treating acute and chronic pain and is evaluating it in an ongoing Phase 1 trial. This patent, as well as other patents the Company has been granted and is currently pursuing, is a key part of South Rampart's global intellectual property (IP) and patent strategy.

Key Points: 
  • The Company is currently developing SRP-001 for treating acute and chronic pain and is evaluating it in an ongoing Phase 1 trial.
  • This patent, as well as other patents the Company has been granted and is currently pursuing, is a key part of South Rampart's global intellectual property (IP) and patent strategy.
  • South Rampart Pharma's novel non-opioid global portfolio now includes granted patents in U.S. and Asia-Pacific territories.
  • Furthermore, regarding the Company's IP strategy in Europe, South Rampart has recently been notified by the European Patent Office (EPO) that the European patent application for SRP-001 has been allowed.

Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients

Retrieved on: 
Wednesday, June 21, 2023
China National Intellectual Property Administration, Patent, Allergy, CNIPA, Food, Diet, IPad, Artificial intelligence, Safety, Algorithm, Patient, IBS, Chinese patent medicine, Environment, Dietary supplement, Medical device, Pharmaceutical industry

The patent encompasses a host of IT methods to evaluate, predict, learn and update the potential health risks associated with consuming specific prepared food items, based on a patient's medical data.

Key Points: 
  • The patent encompasses a host of IT methods to evaluate, predict, learn and update the potential health risks associated with consuming specific prepared food items, based on a patient's medical data.
  • The technology could also recommend alternative packaged or prepared foods that do not contain the previously identified harmful food ingredient.
  • This patent further strengthens the Company’s robust intellectual property portfolio in the area of science, diet and technology.
  • The allowed patent application number in China is 201680054790.9 and can be viewed at: https://biomerica.com/inFoods/our-technology/

Salipro Biotech Obtains Granted Patents in the United States and China for Direct Extraction of Membrane Proteins and Library Generation

Retrieved on: 
Wednesday, September 7, 2022
GPCR, Ion, CEO, Technology, Research, Patent, Chinese patent medicine, IA, Prosaposin, Library, Cell, SLC, China National Intellectual Property Administration, G protein-coupled receptor, Therapy, News, IP, Membrane protein, Business, Drug discovery, Drug development, Biotechnology, Fine chemical, Pharmaceutical industry

STOCKHOLM, Sept. 7, 2022 /PRNewswire/ -- Salipro Biotech AB, a Swedish biotech company with a leading technology platform for the stabilization of membrane proteins for drug development, announced today that its patent entitled "Saposin lipoprotein particles and libraries from crude membranes" has been issued by both the U.S. Patent and Trademark Office (U.S. Patent No. 11,346,843B2) and by the China National Intellectual Property Administration (Chinese Patent No. ZL201780050737.6). The patents cover the company's novel method of direct extraction of membrane proteins (DirectMX®) from cells or crude membranes to enable drug development for challenging drug targets, as well as the generation of Salipro libraries representing the membrane proteome, the particles themselves and their use in drug discovery and membrane protein research, amongst others. The Salipro® technology enables the development of novel therapeutics against drug targets that previously could not be investigated.

Key Points: 
  • The Salipro technology enables the development of novel therapeutics against drug targets that previously could not be investigated.
  • The award of these patents further strengthens Salipro Biotech's global intellectual property portfolio, with various patents already granted i.a.
  • Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics.
  • To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies.

ENDRA Life Sciences Awarded Two Additional Chinese Patents for its TAEUS® System

Retrieved on: 
Monday, July 11, 2022
Health Technology, Science, Health, Other Science, Temperature, Analysis, COVID-19, Non-alcoholic fatty liver disease, Risk, U.S. Securities and Exchange Commission, Industry, Securities Exchange Act of 1934, Liver, Inflammation, NASH, Method, 1836 U.S. Patent Office fire, Financial condition report, Chinese patent medicine, China National Intellectual Property Administration, Element, Health, Forward-looking statement, NAFLD, Technology, MRI, Securities Act of 1933, NDRA, Result, Security (finance), Annual report, NASDAQ, 3D printing, Medical imaging

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), announces that the Chinese National Intellectual Property Administration has issued two new patents to ENDRA, Chinese Patent No.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), announces that the Chinese National Intellectual Property Administration has issued two new patents to ENDRA, Chinese Patent No.
  • We are delighted to announce our 14th and 15th issued patents in China, which provide intellectual property protection through 2040.
  • About ENDRA Life Sciences Inc.
    ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care.
  • Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

ENDRA Life Sciences Issued Additional U.S. and Chinese Patents for its TAEUS® System

Retrieved on: 
Tuesday, May 10, 2022
Research, Technology, Medical Devices, Other Technology, Other Health, Biotechnology, Hardware, General Health, Health, Science, COVID-19, U.S. Securities and Exchange Commission, Forward-looking statement, Data management, MRI, Health, NASDAQ, Non-alcoholic fatty liver disease, Result, Securities Exchange Act of 1934, Securities Act of 1933, Security (finance), Temperature, Inflammation, Chinese patent medicine, Risk, Maritime Transportation Security Act of 2002, Industry, Annual report, Patent, Analysis, NAFLD, Exchange, 1836 U.S. Patent Office fire, NASH, Liver, Financial condition report, Technology, NDRA, Medical imaging

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), announces the issuance of four new patents, two in the U.S. and two in China.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), announces the issuance of four new patents, two in the U.S. and two in China.
  • ENDRAs intellectual property portfolio now includes 90 assets, including 46 issued patents worldwide providing protection for the TAEUS system with its novel hybrid ultrasound and thermoacoustic imaging technology.
  • Although this technology was developed for the TAEUS system, it has broad applicability within the healthcare industry and as such, represents an additional licensing opportunity.
  • About ENDRA Life Sciences Inc.
    ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care.

ENDRA Life Sciences Strengthens TAEUS® System Global Intellectual Property Protection with Issuance of 10th and 11th Chinese Patents

Retrieved on: 
Wednesday, March 30, 2022
Research, Practice Management, Biotechnology, Other Health, Radiology, Health, General Health, Other Science, Science, Chinese patent medicine, Non-alcoholic fatty liver disease, NASDAQ, Partnership, Patent, Analysis, Forward-looking statement, China National Intellectual Property Administration, Sound, Calibration, Liver, Research, Risk, Financial condition report, U.S. Securities and Exchange Commission, RF, Health, NASH, Industry, Technology, Thermoacoustic imaging, Securities Exchange Act of 1934, Inflammation, Securities Act of 1933, NDRA, COVID-19, NAFLD, Result, Maritime Transportation Security Act of 2002, News, MRI, Annual report, Temperature, Security (finance), Medical imaging

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), announces that the Chinese National Intellectual Property Administration has issued ENDRA two new patents, Chinese Patent No.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), announces that the Chinese National Intellectual Property Administration has issued ENDRA two new patents, Chinese Patent No.
  • ZL 2019 8 00400927 (the 927 patent) titled Method and System for Determining Fractional Fat Content of Tissue, and Chinese Patent No.
  • "We continue to enhance our intellectual property portfolio to protect our technology in priority global markets.
  • The 250 patent provides more robust intellectual property protection for the TAEUS platform related to its disruptive scanning approach.

ZANOPRIMA LIFESCIENCES FILES PATENT INFRINGEMENT ACTION AGAINST HANGSEN INTERNATIONAL TO ENFORCE ITS GROUNDBREAKING ENZYMATIC PROCESS FOR SYNTHESIZING (S)-NICOTINE

Retrieved on: 
Thursday, March 17, 2022
CGMP, Alkaloid, Nicotine, Patent, Herbal cigarette, Complaint, Death, Multimedia, District court, 1836 U.S. Patent Office fire, Douglas v. U.S. District Court ex rel Talk America, ESG, Tobacco, CEO, Chinese patent medicine, Name, Formaldehyde, Goal, Carcinogen, Movement, FDA, Disease, Fine chemical, Generic drug

WACO, Texas, March 17, 2022 /PRNewswire/ -- Zanoprima Lifesciences Ltd. filed a Complaint for Patent Infringement against Hangsen International Group Ltd. ("Hangsen") in the U.S. District Court in the Western District of Texas, Civil Action No.

Key Points: 
  • WACO, Texas, March 17, 2022 /PRNewswire/ -- Zanoprima Lifesciences Ltd. filed a Complaint for Patent Infringement against Hangsen International Group Ltd. ("Hangsen") in the U.S. District Court in the Western District of Texas, Civil Action No.
  • In its Complaint, Zanoprima Lifesciences alleges that Hangsen has violated its patent entitled "Process for Making (S)-Nicotine," ( U.S. Patent No.
  • 10,913,962 ) ("Zanoprima's Patent") through Hangsen's manufacture and importation into the U.S. market products containing synthetic nicotine that are manufactured using Zanoprima Lifescience's patented and groundbreaking process.
  • Zanoprima's Complaint alleges that, after publication of Zanoprima's Patent, Hangsen filed a Chinese Patent Application describing a process that copied the process invented by Zanoprima.